Resumen acción SAVA
Cassava Sciences, Inc, empresa biotecnológica en fase clínica, desarrolla fármacos para enfermedades neurodegenerativas.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Cassava Sciences, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.03 |
| 52 Week High | US$32.10 |
| 52 Week Low | US$12.32 |
| Beta | -0.40 |
| 1 Month Change | -1.22% |
| 3 Month Change | -17.04% |
| 1 Year Change | -14.36% |
| 3 Year Change | -34.59% |
| 5 Year Change | 1,728.70% |
| Change since IPO | -86.27% |
Noticias y actualizaciones recientes
Recent updates
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28Cassava Sciences Stock: Here We Go Again
Dec 21Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
Dec 02Cassava Sciences Gets Underway Putting Simufilam To The Test
Nov 24Cassava Sciences: Data Rules!
Nov 17Cassava Sciences' Hypothesis Raises Doubts
Nov 08Cassava Sciences Stock: Massive Potential Marred By Controversy
Nov 01Cassava Sciences: Welcome To The Casino
Oct 25Has Cassava Sciences Put Out The Fire For Now?
Sep 28Cassava Sciences: Medical History In The Making
Sep 21Cassava Sciences: One Doubtful Drug For One Doubtful Indication
Sep 15We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth
Sep 14More On Cassava Sciences' Controversy
Sep 04Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor
Aug 265 Reasons Cassava Sciences Could Still Be The Most Undervalued Stock In The Market
Jul 27Rentabilidad de los accionistas
| SAVA | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -17.2% | -3.2% | -3.5% |
| 1Y | -14.4% | 11.7% | 20.2% |
Rentabilidad vs. Industria: SAVA obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del 20.2%.
Rentabilidad vs. Mercado: SAVA obtuvo unos resultados inferiores a los del mercado US, que fue del 22.3% el año pasado.
Volatilidad de los precios
| SAVA volatility | |
|---|---|
| SAVA Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: El precio de las acciones de SAVA ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de SAVA (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1998 | 29 | Remi Barbier | www.cassavasciences.com |
Cassava Sciences, Inc. es una empresa de biotecnología en fase clínica que desarrolla fármacos para enfermedades neurodegenerativas. Su principal candidato a producto terapéutico es el simufilam, un fármaco de molécula pequeña, que ha completado el ensayo clínico de fase 2; y el candidato a producto de diagnóstico en investigación es SavaDx, un biomarcador/diagnóstico basado en la sangre para detectar la enfermedad de Alzheimer. La empresa se conocía anteriormente como Pain Therapeutics, Inc. y cambió su nombre a Cassava Sciences, Inc. en marzo de 2019.
Resumen de fundamentos de Cassava Sciences, Inc.
| Estadísticas fundamentales de SAVA | |
|---|---|
| Capitalización bursátil | US$865.35m |
| Beneficios(TTM) | -US$97.22m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-9.4x
Ratio precio-beneficio (PE)¿Está SAVA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de SAVA | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$89.42m |
| Beneficio bruto | -US$89.42m |
| Otros gastos | US$7.79m |
| Beneficios | -US$97.22m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.25 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado SAVA a largo plazo?
Ver rendimiento histórico y comparativa